K. Tada

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

H. Asaoku, S. Iida, D. Maruyama, 2020, Cancer science.

Lipid peroxidation and the subsequent cell death transmitting from ferroptotic cells to neighboring cells

H. Nishizawa, Mitsuyo Matsumoto, K. Igarashi, 2021, Cell Death & Disease.

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study

P. Moreau, K. Ishizawa, M. Uchiyama, 2022, Japanese journal of clinical oncology.

Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.

S. Iida, Kihyun Kim, M. Matsumoto, 2022, Clinical lymphoma, myeloma & leukemia.

Intestinal Transplantation at a Single Institution in Japan.

S. Yamaki, M. Nio, Hironori Kudo, 2021, Transplantation proceedings.

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.

P. Moreau, Kihyun Kim, K. Ishizawa, 2023, Clinical lymphoma, myeloma & leukemia.

Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

H. Asaoku, S. Iida, D. Maruyama, 2022, Hematological oncology.